MedTrace Logo

PCV13 + Hepatitis a Vaccine for Adults

NCT01926860 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 305

Last updated 2024-12-05

No results posted yet for this study

Summary

The present study explores whether a simultaneously given hepatitis A vaccine (Epaxal) will have an impact on the immune response to PCV13 (pneumococcal conjugate vaccine; Prevenar13) vaccine in adults. The immune response to PCV13 is measured as levels of serotype specific serum antibodies and their opsonophagocytic activity. The results of volunteers receiving PCV13 and Epaxal will be compared to that in a control groups of adults receiving either hepatitis A or PCV13 vaccines only.

Conditions

  • Measurement of Immune Response to Prevenar13
  • Measurement of Immune Response to Hepatitis a

Interventions

BIOLOGICAL

Prevenar13

BIOLOGICAL

Hepatitis A vaccine

Sponsors & Collaborators

  • Helsinki University Central Hospital

    lead OTHER

Principal Investigators

  • Anu Kantele, Assoc. prof. · Helsinki University Central Hospital

  • Lars Rombo, Professor · Sörmland County Council, Centre for Clinical Research

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-08-24
Primary Completion
2019-10-28
Completion
2020-04-28

Countries

  • Finland
  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01926860 on ClinicalTrials.gov